01 January 2002
Combination of pamidronate and thalidomide in the therapy of treatment-resistantmultiple myeloma.
Wojciech Baran, Hanna Ciepłuch, Andrzej HellmannMed Sci Monit 2002; 8(4): PI31-36 :: ID: 420859
Abstract
BACKGROUND: Bisphosphonates inhibit the activity of osteoclasts and demonstrateantitumor effect, involving induction of plasmocyte apoptosis, blocking of angiogenesis, stimulationof Tgd lymphocytes and inhibition of metalloproteinases. Bisphosphonates combined with thalidomide, adrug possessing confirmed anti-myeloma activity, seem to have potential favorable effect in patientswith treatment-resistant multiple myeloma with advanced osteolytic lesions. MATERIAL/METHODS: 13 patientswith treatment-resistant multiple myeloma with advanced osteolytic lesions received combined pamidronateand thalidomide therapy. All the patients underwent detailed clinical and laboratory control once a month.Pamidronate was used at 90 mg i.v. dose administered at 4-week intervals, and thalidomide at doses escalatedfrom 200 mg/d in the first week to 400 mg/d after 3 weeks of the therapy. The mean duration of treatmentwas 12 weeks with a range of 3 to 36 weeks. RESULTS: 7 patients (53%) receiving pamidronate and thalidomidetherapy demonstrated good response involving at least 25% reduction of monoclonal protein levels in comparisonwith baseline. All these patients reported improvement of osteodynia symptoms, and 3 of them - theircomplete regression. 70% patients experienced side effects (dizziness, constipation, somnolence, polyneuropathy)due to thalidomide administration CONCLUSIONS: Good response to combined pamidronate and thalidomidetherapy can be expected in at least 50% of patients with treatment-resistant multiple myeloma with advancedosteolytic lesions.
Keywords: Aged, 80 and over, Angiogenesis Inhibitors, Antineoplastic Combined Chemotherapy Protocols, Constipation, Diphosphonates, Disorders of Excessive Somnolence, Dizziness, Multiple Myeloma, Myeloma Proteins, Osteolysis, Pain, Remission Induction, thalidomide
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Clinical Research
Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe PsoriasisMed Sci Monit In Press; DOI: 10.12659/MSM.943360
14 Mar 2024 : Clinical Research
Renal Dysfunction Increases Risk of Adverse Cardiovascular Events in 5-Year Follow-Up Study of Intermediate...Med Sci Monit In Press; DOI: 10.12659/MSM.943956
15 Mar 2024 : Clinical Research
Impact of One-Lung Ventilation on Oxygenation and Ventilation Time in Thoracoscopic Heart Surgery: A Compar...Med Sci Monit In Press; DOI: 10.12659/MSM.943089
14 Mar 2024 : Clinical Research
Differential DHA and EPA Levels in Women with Preterm and Term Births: A Tertiary Hospital Study in IndonesiaMed Sci Monit In Press; DOI: 10.12659/MSM.943895
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952